Modulating the Tumor Microenvironment with T Cell Bispecifics

Professor Sumit K. Subudhi shares his insights on modulating the tumor microenvironment with T Cell bispecifics at SITC's 40th Anniversary Annual Meeting.

How to optimize PD1/PDL1 treatment?

Professor Gordon J. Freeman shares his insights on how to optimize PD1/PDL1 treatment at SITC's 40th Anniversary Annual Meeting.

Phase I Trial of DOC1021 Cell-Based Immunotherapy for Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma

Professor William Decker discusses the Phase I Trial of DOC1021 cell-based immunotherapy for resectable or borderline resectable pancreatic ductal adenocarcinoma at SITC's 40th Anniversary Annual Meeting.

Primary analysis of patients with high-risk localized, locally recurrent, or regionally advanced cutaneous squamous cell carcinoma treated with neoadjuvant PD-1 therapy

Professor Gino In presented data from the NeoPOWER trial, to study the role of neoadjuvant PD-1 alone in CSCC at SITC's 40th Anniversary Annual Meeting.

Reprogramming the Immune Microenvironment to Intercept Lung Adenocarcinoma Precancer

Professor Jianjun Zhang shares his insights on reprogramming the immune microenvironment to intercept lung adenocarcinoma precancer at SITC's 40th Anniversary Annual Meeting.

State of the art tumor-targeting IL-12 immunocytokine therapies

Dr. Gregory Conn shares his insights on state of the art tumor-targeting IL-12 immunocytokine therapies after SITC's 40th Anniversary Annual Meeting.